MagForce AG operates in the field of nanotechnology-based cancer therapy in Germany and Poland. It offers NanoTherm, a therapy for the treatment of brain tumors; NanoPlan, a software that supports the attending physician in preparing the ideal treatment plan for the NanoTherm therapy; and NanoActivator, a magnetic field generator. MagForce AG was founded in 1997 and is headquartered in Berlin, Germany.
Research context
MagForce AG appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
MagForce AG is currently in a long term downtrend where the price is trading 10.9% below its 200 day moving average.
From a valuation standpoint, the stock is 92.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 101.3.
Based on the above factors, MagForce AG gets an overall score of 1/5.